Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - (Placebo-Controlled, Double Blind and Randomized Phase III Study of Intravaginal Prasterone)

NCT03287232 is registered in ClinicalTrials.gov with EndoCeutics Inc. as lead sponsor.

NCT NCT03287232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03287232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - (Placebo-Controlled, Double Blind and Randomized Phase III Study of Intravaginal Prasterone)
Lead sponsor
EndoCeutics Inc.
Phase
Phase 3
Overall status
Completed
Start date
October 16, 2017
Completion date
July 22, 2019
Enrollment
653 (actual)
Sites
69

Conditions

As the registry lists them; a condition with its own page is linked.

hypoactive sexual desire disorder